---
title: "Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease  ( CTAD )  Conference"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/218398489.md"
description: "Eisai Co., Ltd. and Biogen Inc. presented findings on lecanemab, an anti-amyloid beta antibody for early Alzheimer's disease, at the CTAD Conference. Long-term studies showed that continued treatment with lecanemab resulted in significant cognitive improvements and reduced disease progression risk. A new method for measuring protofibrils in cerebrospinal fluid was developed, revealing a strong correlation with neurodegenerative biomarkers. The data suggest that early initiation of lecanemab treatment may positively impact disease progression in early Alzheimer's patients, with no new safety concerns reported over three years of treatment."
datetime: "2024-10-31T00:04:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/218398489.md)
  - [en](https://longbridge.com/en/news/218398489.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/218398489.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/218398489.md) | [繁體中文](https://longbridge.com/zh-HK/news/218398489.md)


# Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease  ( CTAD )  Conference

\-New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical ...

### 相关股票

- [Biogen (BIIB.US)](https://longbridge.com/zh-CN/quote/BIIB.US.md)

## 相关资讯与研究

- [Samsung Biologics Acquires GSK's Manufacturing Facility in US](https://longbridge.com/zh-CN/news/281465578.md)
- [Biogen, with $5.6B Apellis buy, builds out immunology offerings](https://longbridge.com/zh-CN/news/281425584.md)
- [FDA approves new high dose Spinraza regimen for SMA](https://longbridge.com/zh-CN/news/281376767.md)
- [BUZZ-Street View: Biogen's $5.6 billion Apellis bet a strategic fit](https://longbridge.com/zh-CN/news/281357962.md)
- [If You Invested $1000 In AstraZeneca Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/zh-CN/news/281048213.md)